CLINICAL CHEMISTRY | SCIENTIFIC ARTICLES
Direct HDL Cholesterol Testing on Automated Clinical Chemistry Analyzers:
Performance, Compatibility and Laboratory Workflow
Explore direct HDL cholesterol measurement on automated clinical chemistry
analyzers, including analytical performance, calibration, reagent stability
and application verification.
1. Why Automated HDL-C Testing Matters
Automated clinical chemistry systems are central to routine lipid testing.
Laboratories need reproducible HDL cholesterol results, efficient sample
handling and methods that can be configured for their installed instruments.
The choice of reagent must therefore consider more than the clinical
relevance of HDL-C: the analytical measuring interval, reagent presentation,
calibration and analyzer-specific application parameters also matter.
Archem Diagnostics Direct HDL Cholesterol (D-HDL-C) is an in vitro
diagnostic assay for the quantitative determination of HDL-C in human
serum and plasma. It is supplied as a ready-to-use liquid, two-reagent
system.
This article examines its documented analytical characteristics and
practical considerations for automated implementation, including
analyzer applications, reagent stability, calibration and quality control.
2. How the Homogeneous Enzymatic Assay Works
The assay uses a homogeneous enzymatic colorimetric method.
Dextran sulfate and magnesium interact with non-HDL lipoproteins,
including LDL, VLDL and chylomicrons, to inhibit their participation
in the enzymatic measurement.
A selective detergent then makes HDL-associated cholesterol available
for the subsequent reaction.
PEG-cholesterol esterase and PEG-cholesterol oxidase participate in
reactions that generate hydrogen peroxide. Peroxidase-mediated color
formation allows photometric measurement; color intensity is
proportional to HDL cholesterol concentration under the specified
conditions.
Because the method is direct, it does not require a separate
precipitation or sample pretreatment step.
This approach is particularly relevant to automated clinical chemistry
laboratories, where reducing manual preparation steps can support
more standardized analytical workflows.
3. Analyzer Applications and Compatibility
An analyzer application is more than a list of compatible brand names.
Each instrument may require specific reagent and sample volumes,
reaction timing, wavelength settings, calibration procedures and
wash sequences.
These parameters must be evaluated for the exact reagent–analyzer
combination to ensure that the method operates within its intended
analytical specifications.
Archem Diagnostics provides analyzer-oriented reagent formats and
application support. Its Validation Center presents the company's
broader analyzer platforms and validation activities.
The presence of an instrument on the corporate Validation Center
page should not, by itself, be interpreted as proof that this
particular HDL-C assay has been validated on every listed model.
Product-specific compatibility should be confirmed using the
relevant HDL-C application documentation.
Explore Analyzer Platforms
Discover analyzer platforms and application solutions
through the Archem Diagnostics Validation Center.
Explore our analyzer application capabilities and
technical solutions for automated clinical chemistry
laboratories.
EXPLORE THE VALIDATION CENTER →
4. Documented Analytical Performance
The manufacturer's instructions for use (IFU, revision V3.5,
August 2023) specify an analytical measuring interval of
3–200 mg/dL, a detection limit of
2.7 mg/dL and a quantitation limit of
3.0 mg/dL.
Linearity is reported up to 200 mg/dL.
The IFU reports within-run coefficients of variation (CV)
of 1.01% at 60.1 mg/dL and 0.60% at 131.1 mg/dL.
Day-to-day CVs were 2.05% at 60.4 mg/dL and
2.18% at 131.1 mg/dL.
Method comparison yielded a correlation coefficient of
r = 0.991 and a Passing–Bablok
relationship of y = 1.015x + 0.96 mg/dL.
These are results obtained under the stated evaluation conditions,
not guarantees of identical performance on every analyzer.
Analytical performance should be considered in relation to
the laboratory's intended clinical application, measurement
requirements and installed analyzer configuration.
Before routine use, laboratories should verify that the
selected application meets their established analytical
performance criteria.
5. Reagent Storage and Stability
Reagent stability is an important operational consideration
for laboratories using automated clinical chemistry systems.
Archem Direct HDL Cholesterol reagents are supplied as
ready-to-use liquids and should be stored at
+2°C to +8°C.
Unopened reagents remain stable until the expiration date
stated on the label when stored under the specified conditions.
The reagents must not be frozen.
The IFU specifies 30 days of stability after opening
under optimum storage conditions at +2°C to +8°C.
On-board stability is not a universal fixed claim.
It depends strongly on analyzer cooling performance and
carry-over characteristics.
Laboratories should establish appropriate handling practices
and verify stability under their operating conditions.
6. Calibration and Quality Control
Accurate HDL cholesterol measurement depends on an appropriate
calibration strategy and a structured quality-control program.
The specified calibrator for Archem Direct HDL Cholesterol
is the Archem HDL-LDL (Arcal Lipid) Calibrator.
The IFU indicates calibration stability of 30 days,
depending on analyzer application characteristics and
cooling capacity.
This interval should not replace calibration triggered
by quality-control failure or other instrument-specific
requirements.
For quality control, the IFU identifies:
-
Arcon N: Level 1 control material.
-
Arcon P: Level 2 control material.
The IFU instructs laboratories to run at least two
control levels once every 24 hours and to establish
their own quality-control scheme.
Control results outside established acceptance limits
require investigation and, according to the IFU,
recalibration.
A structured quality-control program supports the
ongoing assessment of analytical stability and helps
laboratories identify potential performance changes
before patient results are reported.
7. Integrating HDL-C Testing into Laboratory Workflows
Successful implementation begins with confirming the
specimen types, reagent pack, instrument settings
and local verification plan.
The IFU accepts human serum and plasma.
For plasma, it identifies lithium heparin,
K2-EDTA and K3-EDTA collection tubes as preferred options.
Before routine reporting, laboratories should review
precision, reportable range, calibration behavior,
interference, carry-over and quality-control rules
as applicable to their analyzer.
Homogeneous direct measurement can simplify laboratory
workflow by eliminating a separate sample precipitation
step.
However, practical throughput, reagent consumption
and cost per reportable result remain dependent on
the analyzer configuration and laboratory workload.
Analyzer-specific application documentation is therefore
an important part of method implementation.
Laboratories should assess the complete analytical process,
including sample handling, reagent loading, calibration,
quality control and result reporting.
8. Conclusion
Direct HDL cholesterol testing combines selective
enzymatic chemistry with the operational requirements
of modern automated clinical chemistry laboratories.
Archem Diagnostics Direct HDL Cholesterol is a
ready-to-use liquid two-reagent assay with documented
analytical performance and defined calibration and
quality-control materials.
Its homogeneous enzymatic methodology eliminates the
need for a separate precipitation step, supporting
integration into automated laboratory workflows.
For a responsible analyzer compatibility decision,
laboratories should use the current IFU together with
the relevant analyzer-specific application documentation
and local performance verification.
The Archem Diagnostics Validation Center provides
a useful starting point for exploring the company's
broader analyzer application capabilities and
technical solutions.
Selected Technical References
-
Archem Diagnostics.
Direct HDL Cholesterol (D-HDL-C), Instructions for Use.
Revision V3.5, August 2023.
-
Clinical and Laboratory Standards Institute (CLSI).
Evaluation of Precision of Quantitative Measurement Procedures.
CLSI EP05-A3, 2014.
-
Clinical and Laboratory Standards Institute (CLSI).
Evaluation of Detection Capability for Clinical Laboratory
Measurement Procedures.
CLSI EP17-A2, 2012.
-
Clinical and Laboratory Standards Institute (CLSI).
Evaluation of Stability of In Vitro Diagnostic Reagents.
CLSI EP25-A, 2009.
-
Clinical and Laboratory Standards Institute (CLSI).
Evaluation of the Linearity of Quantitative
Measurement Procedures.
CLSI EP06-A, 2003.